PAMELA SANTIAGO: Open Payments
NPI 1891971347 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,601 in 101 payments from 13 companies in 2025. Trend: 2023 $596 · 2024 $2,017 · 2025 $2,601
Food & beverage: $2,601
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $796 |
| ABBVIE INC. | 30 | $629 |
| Otsuka America Pharmaceutical, Inc. | 17 | $383 |
| Lundbeck LLC | 6 | $146 |
| Vanda Pharmaceuticals Inc. | 5 | $141 |
| Neurocrine BioSciences, Inc. | 9 | $136 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $83 |
| Janssen Biotech, Inc. | 3 | $80 |
| Janssen Pharmaceuticals, Inc | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
Products named: CAPLYTA, VRAYLAR, REXULTI, ABILIFY ASIMTUFII, FANAPT, INGREZZA, SPRAVATO, UZEDY.
Industry payments across NY — which companies pay providers there.
